A monoclonal antibody targeting the dimer interface of epidermal growth factor receptor (EGFR)

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) is a key target in epithelial cancer treatment.
• Current EGFR antagonists face challenges with low response rates and resistance, often due to receptor hypermutation and heterodimerization.
• Targeting the conserved dimer interface of EGFR presents a novel therapeutic strategy.

Purpose of the Study:

• To develop and characterize a monoclonal antibody (mAb) targeting the EGFR dimer interface.
• To evaluate the efficacy of this novel antibody in inhibiting cancer cell growth and inducing apoptosis.

Main Methods:

• Development of a monoclonal antibody (mAb) named Antidimer 5G9 targeting the EGFR dimer interface.
• Characterization of Antidimer 5G9's binding affinity and specificity to human and mouse EGFR.
• Assessment of Antidimer 5G9's in vitro efficacy on human breast cancer cells (MDA-MB-231) and mouse Lewis lung cancer cells (LLC).

Main Results:

• Antidimer 5G9, an IgG1 mAb, demonstrated high affinity binding (1.837×10^9 L/mol) to EGFR.
• The antibody specifically recognized and bound to human and mouse EGFR on cancer cell surfaces.
• Antidimer 5G9 effectively inhibited the growth of MDA-MB-231 and LLC cells, inducing apoptosis.

Conclusions:

• Targeting the EGFR dimer interface with Antidimer 5G9 is a feasible and effective strategy.
• This approach holds potential for overcoming resistance mechanisms and improving clinical outcomes of anti-EGFR therapies.
• Further studies are warranted to explore the clinical application of this novel anti-EGFR drug development strategy.